pubmed-article:16386906 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:16386906 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
pubmed-article:16386906 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
pubmed-article:16386906 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
pubmed-article:16386906 | lifeskim:mentions | umls-concept:C0001758 | lld:lifeskim |
pubmed-article:16386906 | lifeskim:mentions | umls-concept:C0205217 | lld:lifeskim |
pubmed-article:16386906 | pubmed:issue | 5 | lld:pubmed |
pubmed-article:16386906 | pubmed:dateCreated | 2006-10-18 | lld:pubmed |
pubmed-article:16386906 | pubmed:abstractText | This study evaluates the risk of acute myeloid leukaemia (AML) in patients treated for breast cancer. We included all 6360 breast cancer patients that were recorded at the Geneva Cancer Registry between 1970 and 1999. Patients were followed for AML occurrence until December 2000. We calculated standardized incidence ratios of AML and identified factors modifying the risk of AML by multivariate Cox analysis. Twelve (0.2%) patients developed AML. In general, patients treated for breast cancer had a 3.5-fold (95% confidence interval (CI): 1.8-6.0) increased risk of developing AML compared with the general population. In particular, patients who were older than 70 years at breast cancer diagnosis and those treated with radiotherapy (with or without chemotherapy) had a significantly increased risk of developing AML. This population-based study confirms that radiotherapy increases the risk of AML. Due to the relatively low number of women treated with chemotherapy without radiotherapy and due to the infrequency of the disease, the question of whether chemotherapy alone increases this risk of AML cannot yet be answered. | lld:pubmed |
pubmed-article:16386906 | pubmed:language | eng | lld:pubmed |
pubmed-article:16386906 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16386906 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:16386906 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:16386906 | pubmed:month | Oct | lld:pubmed |
pubmed-article:16386906 | pubmed:issn | 0960-9776 | lld:pubmed |
pubmed-article:16386906 | pubmed:author | pubmed-author:SchäferPP | lld:pubmed |
pubmed-article:16386906 | pubmed:author | pubmed-author:KurtzJJ | lld:pubmed |
pubmed-article:16386906 | pubmed:author | pubmed-author:SappinoA PAP | lld:pubmed |
pubmed-article:16386906 | pubmed:author | pubmed-author:FiorettaGG | lld:pubmed |
pubmed-article:16386906 | pubmed:author | pubmed-author:BouchardyCC | lld:pubmed |
pubmed-article:16386906 | pubmed:author | pubmed-author:RenellaRR | lld:pubmed |
pubmed-article:16386906 | pubmed:author | pubmed-author:VlastosGG | lld:pubmed |
pubmed-article:16386906 | pubmed:author | pubmed-author:VerkooijenH... | lld:pubmed |
pubmed-article:16386906 | pubmed:author | pubmed-author:Neyroud-Caspa... | lld:pubmed |
pubmed-article:16386906 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:16386906 | pubmed:volume | 15 | lld:pubmed |
pubmed-article:16386906 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:16386906 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:16386906 | pubmed:pagination | 614-9 | lld:pubmed |
pubmed-article:16386906 | pubmed:meshHeading | pubmed-meshheading:16386906... | lld:pubmed |
pubmed-article:16386906 | pubmed:meshHeading | pubmed-meshheading:16386906... | lld:pubmed |
pubmed-article:16386906 | pubmed:meshHeading | pubmed-meshheading:16386906... | lld:pubmed |
pubmed-article:16386906 | pubmed:meshHeading | pubmed-meshheading:16386906... | lld:pubmed |
pubmed-article:16386906 | pubmed:meshHeading | pubmed-meshheading:16386906... | lld:pubmed |
pubmed-article:16386906 | pubmed:meshHeading | pubmed-meshheading:16386906... | lld:pubmed |
pubmed-article:16386906 | pubmed:meshHeading | pubmed-meshheading:16386906... | lld:pubmed |
pubmed-article:16386906 | pubmed:meshHeading | pubmed-meshheading:16386906... | lld:pubmed |
pubmed-article:16386906 | pubmed:meshHeading | pubmed-meshheading:16386906... | lld:pubmed |
pubmed-article:16386906 | pubmed:meshHeading | pubmed-meshheading:16386906... | lld:pubmed |
pubmed-article:16386906 | pubmed:meshHeading | pubmed-meshheading:16386906... | lld:pubmed |
pubmed-article:16386906 | pubmed:meshHeading | pubmed-meshheading:16386906... | lld:pubmed |
pubmed-article:16386906 | pubmed:meshHeading | pubmed-meshheading:16386906... | lld:pubmed |
pubmed-article:16386906 | pubmed:meshHeading | pubmed-meshheading:16386906... | lld:pubmed |
pubmed-article:16386906 | pubmed:meshHeading | pubmed-meshheading:16386906... | lld:pubmed |
pubmed-article:16386906 | pubmed:meshHeading | pubmed-meshheading:16386906... | lld:pubmed |
pubmed-article:16386906 | pubmed:year | 2006 | lld:pubmed |
pubmed-article:16386906 | pubmed:articleTitle | Increased risk of acute myeloid leukaemia after treatment for breast cancer. | lld:pubmed |
pubmed-article:16386906 | pubmed:affiliation | Geneva Cancer Registry, Institute for Social and Preventive Medicine, University of Geneva, 55 Boulevard de la Cluse, 1205 Geneva, Switzerland. | lld:pubmed |
pubmed-article:16386906 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:16386906 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16386906 | lld:pubmed |